Related Experiment Videos
The hemophilias: progress and problems.
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Seminars in Hematology
|December 14, 1999
Summary
Hemophilia care has advanced significantly with safer factor concentrates and recombinant therapies. Future gene replacement therapy offers hope for a cure for this inherited blood disorder.
Area of Science:
- Hematology
- Medical Genetics
- Virology
Background:
- Hemophilia, a severe inherited blood coagulation disorder, has seen major advancements in care since the 1970s.
- Early hemophilia treatments using pooled plasma concentrates carried risks of transmitting viral infections like HIV and hepatitis.
Observation:
- The 1980s highlighted the dangers of viral transmission through plasma-derived factor concentrates.
- Scientific response led to the development of viral inactivation methods during concentrate manufacturing.
Findings:
- Modern hemophilia care benefits from viral-inactivated concentrates and recombinant factor production, drastically reducing infection risks.
- Polymerase chain reaction (PCR) aids in identifying gene mutations, enabling carrier detection and prenatal diagnosis.
Implications:
- Continued progress in hemophilia management includes addressing antibody inhibitors and potential new infectious risks.
- Gene replacement therapy represents a promising future direction for potentially curing hemophilia.